Total Valuation
Immix Biopharma has a market cap or net worth of $710.48M. The enterprise value is $418.48M.
Market Cap$710.48M
Enterprise Value$418.48M
Share Statistics
Immix Biopharma has 71,189,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,189,950
Owned by Insiders17.21%
Owned by Institutions17.11%
Financial Efficiency
Immix Biopharma’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -28.68%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-28.68%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-1.64M
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immix Biopharma is ―. Immix Biopharma’s PEG ratio is -0.34.
PE Ratio―
PS Ratio0.00
PB Ratio1.84
Price to Fair Value1.84
Price to FCF-6.99
Price to Operating Cash Flow-11.91
PEG Ratio-0.34
Income Statement
In the last 12 months, Immix Biopharma had revenue of 0.00 and earned -29.44M in profits. Earnings per share was -0.89.
Revenue0.00
Gross Profit-364.50K
Operating Income-27.21M
Pretax Income-29.40M
Net Income-29.44M
EBITDA-29.04M
Earnings Per Share (EPS)-0.89
Cash Flow
In the last 12 months, operating cash flow was -32.07M and capital expenditures -697.70K, giving a free cash flow of -32.77M billion.
Operating Cash Flow-32.07M
Free Cash Flow-32.77M
Free Cash Flow per Share-0.46
Dividends & Yields
Immix Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change382.13%
50-Day Moving Average9.24
200-Day Moving Average6.49
Relative Strength Index (RSI)61.67
Average Volume (3m)1.60M
Important Dates
Immix Biopharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Immix Biopharma as a current ratio of 10.01, with Debt / Equity ratio of 1.23%
Current Ratio10.01
Quick Ratio10.01
Debt to Market Cap0.00
Net Debt to EBITDA3.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immix Biopharma has paid 37.72K in taxes.
Income Tax37.72K
Effective Tax Rate>-0.01
Enterprise Valuation
Immix Biopharma EV to EBITDA ratio is -2.74, with an EV/FCF ratio of -3.23.
EV to Sales0.00
EV to EBITDA-2.74
EV to Free Cash Flow-3.23
EV to Operating Cash Flow-3.32
Balance Sheet
Immix Biopharma has $90.58M in cash and marketable securities with $1.04M in debt, giving a net cash position of $89.54M billion.
Cash & Marketable Securities$90.58M
Total Debt$1.04M
Net Cash$89.54M
Net Cash Per Share$1.26
Tangible Book Value Per Share$2.85
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immix Biopharma is $20.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.25
Price Target Upside95.65% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-27.17%